Barinthus Biotherapeutics
Barinthus Biotherapeutics is a UK-headquartered clinical-stage biopharmaceutical company developing immunotherapies designed to reprogram the immune system to treat chronic infectious diseases, autoimmune conditions, and cancer. The company's lead clinical assets include VTP-300 (an immunotherapeutic for chronic hepatitis B being developed in a collaboration and license agreement with the University of Oxford and in combination studies with Arbutus Biopharma), VTP-1100 (a neoantigen cancer immunotherapeutic partnered with Cancer Research UK), and SNTI acquired imetelstat-adjacent telomere programs. The company operates as a UK-incorporated ADR listed on Nasdaq.
Company Info
Upcoming Milestones & Key Dates
Phase 2 interim updates for VTP-300 in chronic hepatitis B
Clinical Development Pipeline
VTP-300
Target: HBV immunotherapeutic (ChAdOx1-HBV / MVA-HBV prime-boost)VTP-1100
Target: Personalized cancer neoantigen vaccineVTP-1000
Target: Modified HLA-DQ-restricted gluten peptide therapeuticRecent News
No recent news updates available for this company.
Leadership Team
Bill Enright
Chief Executive Officer
Careers & Job Openings